Minimising the risk of heparin-induced osteoporosis during pregnancy

Bibliography

• CONCENSUS DEVELOPMENT CONFERENCE: Prophylaxis and treatment of osteoporosis. Osteoporosis mt. (1991) 1:114–117.
   PubMedGoogle Scholar
• ••Evidence-based guidelines onthe diagnosis, prevention, and treatment of osteoporosis.
   Google Scholar
• BLACK D, COOPER C: Epidemiology of fractures and assessment of fracture risk. Clin. Lab. Med. (2000) 20:439–453.
   PubMed Web of Science ®Google Scholar
• •A summary of the risk factors, prevalence, and incidence of osteporosis in men and women.
   Google Scholar
• HANSEN LB, VONDRACOK SF: Prevention and treatment of nonpostmenopausal osteoporosis. Am. J. Health-Syst. Pharm. (2004) 61:2637–2656.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of medicationsthat have been implicated as secondary causes of osteoporosis.
   Google Scholar
• CUMMINGS S, BATES D, BLACK D: Clinical use of bone densitometry: scientific review. JAMA (2002) 288:1889–1890.
   PubMed Web of Science ®Google Scholar
• •A detail scientific review of the use of bone densitometry in the diagnosis of osteopenia and osteoporosis.
   Google Scholar
• WORLD HEALTH ORGANIZATION: Assessment of fracture risk its application to screening for postmenopausal osteoporosis. World Health Organ. Tech. Rep. Ser. (1994) Geneva: WHO.
   Google Scholar
• ••Frequently cited report providing theconsensus defmition of osteopenia and osteoporosis based on BMD measurements.
   Google Scholar
• CHRISTODOULOU C, COOPER C: What is osteoporosis? Postgrad. Med. J. (2003) 79:133–138.
   Google Scholar
• •A brief clinical review of osteoporosis.
   Google Scholar
• PEACOCK M, TURNER CH, ECONS MJ, FOROUD T: Genetics of osteoporosis. Endocr. Rev (2002) 23:303–326.
   PubMed Web of Science ®Google Scholar
• •A scholarly review of genetic factors involved in the prognosis of osteoporosis.
   Google Scholar
• SEEMAN E: Invited Review: Pathogenesis of osteoporosis. J. Appl. Physiol (2003) 95:2142–2151.
   PubMed Web of Science ®Google Scholar
• ••A careful review of the pathogenesis of osteoporosis in men and women.
   Google Scholar
• TANNIRANDORN P, EPSTEIN S: Drug-induced bone loss. Osteoporosis Int (2000) 11:637–659.
   PubMed Web of Science ®Google Scholar
• •Describes the association between dose and duration and heparin-induced osteoporosis.
   Google Scholar
• BHANDARI M, HIRSH J, WEITZ JI, YOUNG E, VENNER TJ, SHAUGHNESSY SG: The effects of standard and low molecular weight heparin on bone module formation in vitro. Thromb. Haemost. (1998) 80:413–417.
   PubMed Web of Science ®Google Scholar
• •A paper that outlines the proposed differences in the mechanism of heparin-and LMWH-induced osteoporosis.
   Google Scholar
• FOLWARCZNA J, JANIEC W, GAWAR M, PYTLIK M, KACZMARCZYK-SEDLAK I, NOWINSKA B: Effects of enoxaparin on histomorphometric parameters of bones in rats. Pol.j Pharmacol (2004) 56:451–457.
   PubMedGoogle Scholar
• FOLWARCZNA J, JANIEC W, SLIWINSKI L: Effects of heparin and low-molecular weight heparins on bone mechanical properties in rats. Thromb. Haemost. (2004) 92:940–946.
   PubMed Web of Science ®Google Scholar
• BATES SM, GREER IA, HIRSH J, GINSBERG JS: Use of antithrombotic agents during pregnancy. Chest (2004) 126:627S–644S.
   Google Scholar
• ••Recently updated evidence-basedguidelines for the use of antithrombotic agents during pregnancy.
   Google Scholar
• HIRSH J, RASCHKE R: Heparin and low-molecular weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic drugs. Chest (2004) 126:188S–203S.
   Google Scholar
• •A scholarly review of the pharmacology, pharmacokinetics, and laboratory monitoring of UFH and LMVVH.
   Google Scholar
• HAWKINS D: Limitations of traditional anticoagulants. Pharmacotherapy (2004) 24 (7 Pt 2):625–655.
   Google Scholar
• •Discusses the advantages in the clinical use of the LMWH and fondaparinux over UFH in the prevention and treatment of venous thromboembolism.
   Google Scholar
• GRIGORIS T, GEROTZIAFAS MM, SAMAMA IE: Heparin induced thrombocytopenia: pathogenesis, epidemiology, diagnosis, and management. Haema (2004) 7:22–34.
   Google Scholar
• DAGER WE, WHITE RH: Treatment of heparin-induced thrombocytopenia. Ann. Pharmacother. (2002) 36:489–503
   PubMed Web of Science ®Google Scholar
• •A review of the treatment options for HIT and considerations in developing a therapeutic approach.
   Google Scholar
• BAUER KA, HAWKINS DW, PETERS PC, PETITOU M, HERBERT J-M, VAN BOECKEL CAA et al.: Fondaparinux, a synthetic pentasaccharide: the first Ma new class of antithrombotic agents - the selective Factor Xa inhibitors. Cardiovasc. Drug Rev (2002) 20:37–52
   Google Scholar
• •A comprehensive review of the biological and pharmacological properties and clinical performance of fondaparinux.
   Google Scholar
• HAWKINS D: Clinical trials with Factor Xa inhibition in the prevention of postoperative venous thromboembolism. Am. I Health-Syst. Pharm. (2003) 60 (Suppl. 7):56–S10.
   Google Scholar
• TURPIE AGG: Future therapeutic directions for Factor Xa inhibition in the prophylaxis and treatment of thrombotic disorders. Am. I Health-Syst. Pharm. (2003) 60 (Suppl. 7):S20–S24.
   Google Scholar
• LAGRANGE F, BRUN J, VERGNES MC, PAOLUCCI F, NADAL T, LENG J-J et al: Fondaparinux sodium does not cross the placental barrier. Clin. Pharmacokinet. (2002) 41 (Suppl. 7):47–49.
   Google Scholar
• WAWRZYNSKA L, TOMKOWSKI WZ, PRZEDLACKI J, HAJDUK B, TORBICKI A: Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathopbysiol Haemost. Tbromb. (2003) 33:64–67.
   PubMed Web of Science ®Google Scholar
• DOUKETIS JD, GINSBERG JS, BURROWS RF: The effects of long-term heparin therapy during pregnancy on bone density. Tbromb. Haemost. (1996) 75:254–257.
   PubMed Web of Science ®Google Scholar
• NELSON-PIERCY C: Heparin-induced osteoporosis. Scand. Rheumatol (1998) 107 (Suppl. 27):68–71.
   Google Scholar
• ••An expert review of heparin-inducedosteoporosis.
   Google Scholar
• DAHLMAN TC: Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am. J. Obstet. Gynecol. (1993) 168:1265–1270.
   PubMed Web of Science ®Google Scholar
• •A large cohort study documenting the Increased risk of vertebral fractures in women who received UFH during pregnancy.
   Google Scholar
• DAHLMAN TC, SJOBER HE, RINGERTZ H: Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am. J. Obstet. Gynecol. (1994) 170:1315–1320.
   PubMed Web of Science ®Google Scholar
• •A prospective observational study that measured the degree of BMD reduction associated with UFH therapy during pregnancy.
   Google Scholar
• RAT R, COHEN H, DAVE M, REGAN L: Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipids antibodies (or antiphospholipid antibodies). BE Med. J. (1997) 314:253–257.
   PubMedGoogle Scholar
• ••A randomised controlled trial thatconfirmed a significant reduction in BMD in high risk women on long-term UFH therapy.
   Google Scholar
• HOWELL R, FIDLER J, LETSKY E, DE SWIET M: The risk of antenatal subcutaneous heparin prophylaxis: a controlled trial. Br. J. Obstet. Gynaecol. (1983) 90:1124–1128.
   PubMedGoogle Scholar
• ••A randomised controlled trial thatdocumented the incidence of severe osteoporosis in patients on long-term heparin therapy.
   Google Scholar
• BARBOUR LA, KICK SD, STEINER JF et al.: A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am. .1 Obstet. Gynecol. (1994) 170:862–869.
   Google Scholar
• •Documents the incidence of osteoporosis as defmed by a 10% reduction in BMD in patients on long-term heparin.
   Google Scholar
• MELISSARI E, PARKER CJ, WILSON NV et al: Use of low molecular weight heparin in pregnancy. Tbromb. Haemost. (1992) 68:652–656.
   PubMed Web of Science ®Google Scholar
• •An observational study showing no loss of BMD in a small sample of female subjects who received LMWH during pregnancy.
   Google Scholar
• SHEFRAS J, FARQUHARSON RG: Bone density studies in pregnant women receiving heparin. Eur. I Obstet. Gynecol. Reprod. Biol. (1996) 65:171–174.
   PubMed Web of Science ®Google Scholar
• •A prospective cohort study that showed a minor reduction of BMD in women who received a LMWH during pregnancy.
   Google Scholar
• NELSON-PIERCY C, LETSKY EA, DE SWIET M: Low molecular weight heparin for obstetric thromboprophylaxis: experience of 69 pregnancies in 61 high risk women. Am. .1 Obstet. Gynecol (1997) 176:1062–1066.
   Google Scholar
• ••Describes the outcome of a large series ofhigh-risk women who received a LMWH during pregnancy.
   Google Scholar
• PETILLA V, LEINONEN P, MARKKOLA A, HIILESMAA V: Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Tbromb. Haemost. (2002) 87:182–186
   PubMed Web of Science ®Google Scholar
• •Reports less bone loss with LMWH than UFHs.
   Google Scholar
• CASELE HL, LAIFER SA: Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. I Matern. Fetal Med. (2000) 9:122–125.
   PubMedGoogle Scholar
• MONREAL M, LAFOZ E, OLIVE A, DEL RIO L, VEDIA C: Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thomboembolism and contraindications to coumarin. Tbromb. Haemost. (1994) 71:7–11.
   PubMed Web of Science ®Google Scholar
• ••A randomised trial of long-term UFH andLMWH that documented a higher rate of spinal fractures in subjects who received UFH.
   Google Scholar
• GRASSMAN ED, LEYA F, FAREED J, LEWIS BE et al.: A randomized trial of the low-molecular weight heparin certoparin to prevent restenosis following coronary angioplasty. J. Invasive Cardiol (2001) 13:723–728.
   PubMedGoogle Scholar
• •A placebo-controlled trial that documents the safety of long-term LMWH therapy in patients following coronary angioplasty.
   Google Scholar
• LAI KN, HO K, CHEUNG RC et al: Effect of low molecular weight heparin on bone metabolism and hyperlipidemia in patients on maintenance hemodialysis. Int. J. Artif Organs (2001) 24:447–455.
   PubMed Web of Science ®Google Scholar
• •Describes the effects of LMWH on bone metabolism in patients undergoing chronic haemodialysis.
   Google Scholar
• MATZIOLIS G, PERKA C, DISCH A, ZIPPEL H: Effects of fondaparinux compared with dalteparin and Unfractionated heparin on human osteoblasts. Cakifi. Tissue Int. (2003) 73:370–379.
   PubMed Web of Science ®Google Scholar
• HANDSCHIN AE, TRENTZ OA, HOERSTRUP SP, KOCK HJ, WANNER GA: Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra®) on human osteoblasts in vitro. Br. Surg. (2005) 92:177–183.
   PubMed Web of Science ®Google Scholar
• CASELE HL, LAIFER SA, WOELKERS DA, VENKATARAMANAN R: Changes in the Pharmacokinetics of the Low-molecular-weight Heparin Enoxaparin Sodium During Pregnancy. Am. J. Obstet. Gynecol (1999) 181:1113–1117
   PubMed Web of Science ®Google Scholar
• •Outlines decreases in anti-Xa levels during pregnancy.
   Google Scholar
• ENSOM HH, STEPHENSON MD: Pharmacokinetics of Low Molecular Weight Heparin and Unfractionated Heparin in Pregnancy. I Soc. Gynecol. Investig. (2004) 11:377–383.
   PubMedGoogle Scholar
• •Describes the pharmacokinetics of dalteparin in pregnancy.
   Google Scholar
• BARBOUR LA, OJA JL, SCHULTZ LK: A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am. J. Obstet. Gynecol (2004) 191:1024–1029.
   PubMed Web of Science ®Google Scholar
• •Documents increased need for dalteparin during pregnancy to maintain anti-factor Xa levels.
   Google Scholar
• NORRIS LA, BONNAR J, SMITH MP, STEER PJ, SAVIDGE G: Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study. Tbromb. Haemost. (2004) 92:791–796.
   PubMed Web of Science ®Google Scholar
• •Supports other research denoting decreased anti-Xa levels in pregnancy.
   Google Scholar
• DUPLAGA BA, RIVERS CW NUTESCU E: Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy (2001) 21:218–234.
   PubMed Web of Science ®Google Scholar
• •Reviews the use of LMWH in various special populations.
   Google Scholar
• LINDHOFF-LAST E, KREUTZENBECK HJ, MAGNANI HN: Treatment of 51 Pregnancies with Danaparoid Because of Heparin Intolerance. Thromb. Haemost. (2005) 93:63–69.
   PubMed Web of Science ®Google Scholar
• •Discusses the rationale for using danaparoid in pregnant patients with a history of HIT.
   Google Scholar
• SORENSEN HT, JOHNSEN SP, LARSEN H, PEDERSEN L, NIELSEN GL, MOLLER M: Birth outcomes in pregnant women treated with low-molecular-weight heparin. Acta Obstet. Gynecol. Scand. (2000) 79:655–659.
   PubMed Web of Science ®Google Scholar
• •Documents safety profile of LMWH in pregnancy.
   Google Scholar
• LAURENT P, DUSSARAT GV, BONAL J et al.: Low molecular weight heparins, A guide to their optimum use in pregnancy. Drugs (2002) 62:463–477.
   PubMed Web of Science ®Google Scholar
• MOLL S: Letter : A low-molecular-weight heparin preparation contraindicated during pregnancy. Am. J. Obstet. Gynecol. (2001) 184:1046.
   PubMed Web of Science ®Google Scholar
• •A letter that draws attention to preservatives used in multidose vials.
   Google Scholar
• Enoxaparin package insert, Aventis.
   Google Scholar
• ROWAN JA, MCCOWAN LM, RUADKIVI PJ, NORTH RA : Enoxaparin treatment in women with mechanical heart valves during pregnancy. Am. I. Obstet. Gynecol. (2001) 185:633–637.
   PubMed Web of Science ®Google Scholar
• BRENNER B, HOFFMAN R, BLUMFELD Z, WEINER Z, YOUNIS JS: Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb. Haemost. (2000) 83:693–697.
   PubMed Web of Science ®Google Scholar
• •Describes the positive results of using LMWH in thrombophilic women with recurrent pregnancy loss.
   Google Scholar
• PAUZNER R, DULITZKI M, LANGEVITZ P, LIVNEH A, KENETT R, MANY A: Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy. Thromb. Haemost. (2001) 86:1379–1384.
   PubMed Web of Science ®Google Scholar
• •Describes the use of LMWH during pregnancy in women with antiphospholipid syndrome.
   Google Scholar
• SCHAMBECK CM, EBERL E, GEISEN U, GROSSMAN R, KELLER F: The impact of dalteparin (Fragmin®) on thrombin generation in pregnant women with venous thromboembolism: significance of the Factor V Leiden mutation. Thromb. Haemost. (2001) 85:782–786.
   PubMed Web of Science ®Google Scholar
• •Presents the positive results observed with the use of LMWH in pregnant women with Factor V Leiden mutation.
   Google Scholar